Source Audit: Verification of Claims, Conflicts of Interest, and Red Flags

1. Audit Methodology: The Evidence Pyramid

#

This audit is based on the evidence hierarchy adopted in evidence-based medicine:

Level 1 (highest):

• Systematic reviews and meta-analyses of randomized controlled trials (RCTs)
• Cochrane Reviews, PRISMA-compliant systematic reviews

Level 2:

• Randomized controlled trials (RCTs) — double-blind, placebo-controlled
• Phase II-III clinical trials registered at ClinicalTrials.gov

Level 3:

• Cohort studies — prospective, with control group
• Case-control studies

Level 4:

• Case reports — individual observations
• Cross-sectional studies

Level 5 (lowest):

• Expert opinion — without systematic data analysis
• Anecdotal evidence — testimonials, self-reports without controls

Verification Criteria

#

For each claim we assessed:

• Number of studies: n ≥ 3 independent RCTs = sufficient for preliminary conclusions
• Design quality: randomization, blinding, placebo control, sample size (n ≥ 30 desirable)
• Replication: Were results reproduced in independent labs?
• Publication bias: Industry funding? Was the trial pre-registered?
• Effect size: Statistically significant ≠ clinically significant (Cohen’s d, OR, RR)
• Conflict of interest: Who conducted and funded the study?

Verdicts

#

• ✅ Confirmed — ≥2 quality RCTs, reproducible results, consensus in scientific community
• ⚠️ Partially confirmed — RCTs exist, but results are contradictory or limited by small samples
• ❌ Refuted — quality studies showed no effect
• [UNVERIFIED] Insufficient data — only in vitro, animal studies, or low-quality observational data

2. Lion’s Mane (Hericium erinaceus) claims: Verification table

#

Detailed Analysis

#

Cognitive functions:

Systematic review by Alzheimer’s Drug Discovery Foundation states: “Cognitive effects with Lion’s mane have been mixed based on small and short-duration clinical trials” [1]. Critical problems:

• Sample sizes too small: n=30-41, insufficient statistical power
• Durations short-term: 4-16 weeks, long-term effects unknown
• Contradictory: one study shows memory worsening [1]

⚠️ WARNING: Marketing claims “boost memory”, “enhance focus” are not supported by existing data. FDA has not approved Lion’s Mane for treatment of cognitive impairment.

NGF stimulation:

In vitro data are compelling: erinacines and hericenones do indeed stimulate NGF synthesis in astroglial cell culture [2]. But:

• In vitro ≠ in vivo
• Unknown if systemic NGF is sufficient for clinical effects
• NGF does not cross blood-brain barrier freely; requires intranasal or direct brain delivery for therapeutic application

Conclusion: Lion’s Mane shows biological activity, but clinical efficacy for cognitive enhancement is not convincingly proven.

3. Psilocybin claims: Full-dose vs. microdosing

#

Detailed Analysis

#

Full-dose psilocybin-assisted therapy:

Evidence base for therapeutic doses (25 mg+) in depression and anxiety is strong:

• Johns Hopkins: 71% of participants with treatment-resistant depression no longer met criteria for MDD after 2 sessions [6]
• Effect persists 12 months without repeat doses [6]
• FDA granted psilocybin Breakthrough Therapy Designation for TRD in 2018

BUT: Efficacy requires psychotherapeutic support (integration therapy), not simply taking a pill. This is psilocybin-assisted therapy, not pharmacotherapy in the classic sense.

Microdosing:

Systematic review 2024 (Polito & Liknaitzky) in Journal of Psychopharmacology: “It is not yet possible to determine whether microdosing is a placebo” [8]. Key findings:

• Largest RCT (2025, Murphy et al.): both groups (microdose LSD and placebo) showed significant improvements in psychological parameters, with no differences between groups [9]
• Only statistically significant differences on acute scales explained by breaking blind (participants guessed which group they were in)
• “Microdosing users make up a self-selected sample with optimistic expectations” → massive expectancy bias [8]

⚠️ WARNING: The microdosing industry (Third Wave, Microdosing Institute) sells courses, guides, retreats based on anecdotal evidence, not RCTs. This is marketing outpacing science.

Conclusion: Full-dose psilocybin = promising therapy for specific indications. Microdosing = most likely placebo.

4. Microdosing LSD claims: Most studied psychedelic for microdoses

#

Detailed Analysis

#

Breaking blind problem:

One critical issue in microdosing research: participants often guess whether they’re taking active substance or placebo, due to:

• Subtle perceptual changes
• Bodily sensations
• Expectancy (they want to feel an effect and interpret any sensations as proof)

2025 study (Murphy et al.) showed: participants who correctly guessed their group reported stronger effects than those who guessed incorrectly [9]. This indicates expectancy-driven reporting, not pharmacological effect.

Neurobiology vs. subjective experience:

Paradox: there are neurobiological changes (6 neuroimaging studies showed changes in brain connectivity [8]), but subjective improvements don’t exceed placebo in well-controlled RCTs.

Possible explanations:

1. Doses too small for clinical effects (threshold problem)
2. Neurobiological changes don’t correlate with functional improvements
3. Placebo effect so strong it masks real (but small) pharmacological effects

Conclusion: For LSD microdosing there is no convincing evidence of clinical benefit exceeding placebo. Self-reported benefits most likely due to expectancy and ritual.

5. Amanita muscaria claims: ☠️ Special attention to safety

#

Detailed Analysis

#

Pharmacology:

Amanita muscaria contains two main psychoactive components:

• Ibotenic acid: NMDA glutamate receptor agonist → excitotoxic, can cause brain lesions in vivo [12]
• Muscimol: formed by decarboxylation of ibotenic acid (drying, heating); potent GABA_A agonist → sedation, anxiolysis, ataxia [12]

Active dose: ~6 mg muscimol or 30-60 mg ibotenic acid ≈ 1 cap of medium A. muscaria [12].

⚠️ CRITICAL PROBLEM: Amount of active substances varies greatly:

• Between regions (Europe vs. North America vs. Siberia)
• Between seasons (spring/summer: up to 10× more ibotenic acid and muscimol than autumn) [12]
• Between individual mushrooms

This makes dosing extremely unreliable.

Clinical effects of poisoning:

Onset: 30 minutes - 2 hours. Symptoms:

• CNS: confusion, dizziness, agitation, ataxia, visual/auditory hallucinations
• Less common: nausea, vomiting, tachycardia, bradycardia, hypertension, hypothermia/hyperthermia, metabolic acidosis [13]
• Rare: seizures, coma

☠️ WARNING: Fatal intoxications extremely rare, but possible at extremely high doses or combined with other substances [13]. Deaths documented in historical journal articles, but with modern medical treatment lethality is close to zero.

Preparation methods:

• Drying: converts ibotenic acid → muscimol via decarboxylation, reducing excitotoxicity
• Parboiling: reduces content of both alkaloids, but also reduces psychoactivity
• Lye treatment: used in Eleusinian Mysteries hypothesis, destroys toxins [see https://lucerna.folkup.app/studies/mushroom-brain-myths/]

⚠️ WARNING: Even after processing, dosing is unpredictable. Homemade preparation = high risk of poisoning.

Conclusion: Amanita muscaria not recommended for recreational use due to:

1. Unpredictability of dosing
2. Unpleasant side effects (nausea, ataxia, confusion)
3. Potential for ibotenic acid to cause brain lesions
4. Absence of therapeutic RCTs

6. Conflict of Interest: Who funds research?

#

Industry-funded vs. independent research

#

Problem: Studies funded by manufacturers are 3-4 times more likely to show positive results than independent ones [14]. This is not necessarily fraud — it’s subtle bias at all stages:

1. Study design: choice of favorable comparators, endpoints, populations
2. Data analysis: selective reporting, p-hacking, HARKing (Hypothesizing After Results are Known)
3. Publication: positive results published, negative ones in “file drawer”
4. Interpretation: overstating significance, downplaying limitations

Paul Stamets / Host Defense

#

Conflict:

• Stamets — owner of Host Defense (largest mushroom supplement manufacturer, 12% market share) [15]
• Stamets — patent holder of Stamets Stack (psilocybin + Lion’s Mane + niacin) [16]
• Stamets — public advocate for mushrooms (lecturer, author, character in “Fantastic Fungi”)

Host Defense funds its own research on products. Results published in peer-reviewed journals, but:

• Stamets — co-author
• Funding disclosure: “Funded by Fungi Perfecti”
• No independent study has reproduced claimed effects of Host Defense products at the same level

⚠️ This does not mean the research is falsified, but requires skeptical assessment.

MAPS (Multidisciplinary Association for Psychedelic Studies) / Lykos

#

Funding:

• MAPS founded by Rick Doblin (1986) as advocacy organization for psychedelic legalization
• Funding: private donations + crowdfunding
• MAPS PBC (Lykos Therapeutics) — commercial division developing MDMA therapy

Conflict:

• MAPS has ideological mission of legalization, not just scientific
• FDA rejected MAPS’s MDMA therapy in 2024, citing flawed study design (MAPP1 and MAPP2 trials) [17]
• Critics point to expectancy bias and breaking blind in MAPS studies

Johns Hopkins Center for Psychedelic Research

#

Funding:

• $17 million from private donors: Steven & Alexandra Cohen Foundation, Matt Mullenweg (co-founder WordPress) [18]
• NIH grant (2021) — first in 50 years federal grant for psychedelics [18]

Conflict:

• Matthew Johnson (Johns Hopkins professor) — clinical advisor for MindMed, public psychedelic pharmaceutical company [18]
• Potential conflict: positive study results → MindMed stock growth

⚠️ BUT: Johns Hopkins has strict disclosure policies and publishes conflicts in articles.

Conclusion: Caveat lector (let the reader beware)

#

When evaluating research always check:

• Funding source
• Author affiliations
• Conflicts of interest statement
• Preregistration (protocol registration before study begins)

Red flags:

• No conflict disclosure
• Industry-funded without independent replication
• Author = manufacturer = advocate (like Stamets)

7. Publication bias: “File drawer problem”

#

Definition

#

Publication bias — systematic tendency to publish studies with positive results and not publish studies with null findings or negative results.

Scale of the problem

#

Meta-analysis by Ioannidis (2005) “Why Most Published Research Findings Are False”:

• ≤50% of published findings are reproduced in independent studies
• For “hot” scientific fields (psychedelics research = hot in 2020s) this percentage is even lower

Psychedelics research and publication bias

#

Problems:

1. Expectancy-driven journals: psychedelic journals (Journal of Psychedelic Studies, Frontiers in Psychiatry: Psychopharmacology) more inclined to publish positive results
2. Media hype: positive findings get PR (Johns Hopkins press releases), negative ones — silence
3. Crowdfunding incentives: Kickstarter projects promise breakthrough results, not null findings

Evidence:

Systematic review of microdosing studies (2024): “13 out of 19 (68%) of microdosing studies with controlled doses reported pre-registration” [8]. This is better than psychology average (~30% preregistration), but still means 32% weren’t pre-registered → risk of HARKing and selective reporting.

Funnel plot asymmetry

#

Funnel plot — graphical method for detecting publication bias. For Lion’s Mane and psilocybin, funnel plots show asymmetry, indicating:

• Absence of negative studies with small samples (small-study effect)
• Probable underreporting of null findings

Replication crisis

#

Psychedelic research has not escaped the replication crisis that has swept psychology and neuroscience:

• Many classic findings (e.g., Leary’s Concord Prison Experiment) don’t reproduce
• Registered Replication Reports (RRRs) for psychedelics are still absent

8. Red flags: How to recognize unreliable sources

#

Consumer checklist

#

🚩 RED FLAGS:

1. Miracle claims: “Cures Alzheimer’s”, “Reverses aging”, “Boosts IQ by 20 points”

   • If it sounds too good to be true — it probably is

2. Testimonials instead of data: “I took Lion’s Mane and my memory improved!” without RCTs

   • Anecdotal evidence = lowest level of evidence

3. Proprietary blends: “Our unique formula contains 10 mushrooms” without dosage disclosure

   • Impossible to verify efficacy; often = underdosing of active components

4. No third-party testing: absence of COA (Certificate of Analysis), HPLC data

   • Possibly low beta-glucan content, presence of fillers

5. References to “ancient wisdom”: “Used in Traditional Chinese Medicine for 2000 years”

   • Traditional use ≠ clinical efficacy; TCM also used mercury and arsenic

6. Buzzwords without substance: “Clinically proven”, “Scientifically validated” without PubMed references

   • Check: are there actual peer-reviewed articles?

7. Celebrity endorsements: “Recommended by Joe Rogan / Tim Ferriss”

   • Celebrities aren’t scientists; their endorsements = marketing, not science

8. No disclaimer: no FDA disclaimer “not intended to diagnose, treat, cure…”

   • DSHEA violation; may receive FDA warning letter

9. Exaggerated language: “Revolutionary”, “Breakthrough”, “Miracle mushroom”

   • Scientific articles use restrained language; marketing — hype

10. Conflict of interest not disclosed: article author = company owner, but not stated

    • Ethical violation; undermines trust

✅ GREEN FLAGS (reliable sources):

#

1. Peer-reviewed publications in top journals (Nature, Science, JAMA Psychiatry, Lancet)
2. Preregistration at ClinicalTrials.gov or OSF
3. Replication by independent labs
4. Transparent funding disclosure
5. Nuanced conclusions: “promising but preliminary”, “requires further research”
6. Third-party verification: ConsumerLab, NSF, USP seals
7. HPLC data in COA with specific beta-glucan numbers
8. Systematic reviews / meta-analyses (Cochrane, PRISMA)

9. Quality of evidence base: Summary by series topics

#

Overall conclusion

#

Biohacking mushroom supplement industry:

• Market growing faster than evidence base
• [MARKETING] Claims outpace science by 5-10 years
• Regulatory gap (DSHEA) allows sales without proof of efficacy
• Product quality extremely variable (fruiting body vs. mycelium on grain)

Psychedelic research:

• Full-dose psilocybin/MDMA = legitimate therapeutic avenue, but Phase III trials needed
• Microdosing = most likely placebo, despite massive hype
• Publication bias and conflicts of interest distort literature

Cultural myths:

• Some (Soma, Eleusinian Mysteries) — intriguing but unverifiable
• Others (Santa-shaman) — debunked
• “Lenin is a mushroom” — brilliant media commentary, not serious theory

Informed consumer:

• Demand RCTs, not testimonials
• Check conflicts of interest
• Skeptically assess miracle claims
• Consult physician before taking supplements

Sources

#

[1] Alzheimer’s Drug Discovery Foundation: Lion’s Mane & Your Brain | Cognitive Vitality [2] Restorative Medicine: Lion’s mane (Hericium erinaceus) [3] PMC: Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines [4] Nootropics Expert: Lion’s Mane [5] PMC: The Acute and Chronic Effects of Lion’s Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults [6] Johns Hopkins Medicine: Efficacy and safety of psilocybin-assisted treatment for major depressive disorder [7] Johns Hopkins Center for Psychedelic and Consciousness Research [8] Polito & Liknaitzky (2024). Is microdosing a placebo? Journal of Psychopharmacology [9] Murphy et al. (2025). Participant Experiences of Microdosed LSD in a 6-Week RCT [10] Big Think: A new spin on the “Stoned Ape Hypothesis” [11] Frontiers: Psilocybin’s effects on cognition and creativity: A scoping review [12] PMC: Toxicological and pharmacological profile of Amanita muscaria [13] PMC: The Deceptive Mushroom: Accidental Amanita muscaria Poisoning [14] Cochrane: Industry sponsorship and research outcome (systematic review) [15] Nutraceuticals World: Mushroom Market Trends in 2025 [16] US Patent: Stamets Stack - Compositions for enhancing neuroregeneration [17] NPR: FDA rejects MDMA therapy for PTSD [18] Johns Hopkins Medicine: Johns Hopkins Center for Psychedelic Research

FolkUp Research Lab | Lucerna